Faculty positions available for #myeloma clinician scientists. Join our @MDAndersonNews #Myeloma Team! Please RT!

RT @JeromeAdamsMD: Wow… never could I have imagined that I’d be at DCA today when scores of American Airlines workers were lined up inside…

#Myeloma Paper of the Day: Evaluation of characteristics and prognostic factors of early progressive disease in newly diagnosed myeloma (<18 months) finds higher median age, β2, LDH, stage, more ultra-high risk disease and lower hemoglobin and eGFR: #mmsm

RT @oncodaily: Myeloma Paper of the Day, February 8th, suggested by @Myeloma_Doc #Cancer #OncoDaily #MedEd #MedX…

#Myeloma Paper of the Day: Cohort study of patients w/ #MGUS (IgG, IgA, or light chain) from nationwide US Veterans Health Administration database suggests maintaining a healthy and stable weight following MGUS diagnosis may prevent progression: #mmsm

Bonus #Myeloma Paper of the Day: Study from our team @MDAndersonNews demonstrating a role for Caseinolytic mitochondrial matrix peptidase in the biology of high-risk myeloma, and approaches to targeting it that could be applicable to the clinic: #mmsm

#Myeloma Paper of the Day: Immune-aging may be linked to clinical malignancy, racial ancestry and vaccine responses in myeloma, suggesting a role for aging-associated changes in immune dysfunction linked to malignant transition: #mmsm

#Myeloma Paper of the Day: Phase 3 CEPHEUS study of Dara+VRd vs. VRd finds MRD-negativity 60.9% for quad vs. 39.4% w/ VRd; ≥CR rates 81.2% vs. 61.6%; sustained MRD negativity (≥12 mos) 48.7% vs. 26.3%, giving 43% lower progression or death risk: #mmsm

#Myeloma Paper of the Day: Patients w/ #MGUS and smoldering myeloma have clinically significant anxiety, depression, PTSD w/ prevalence of 27%, 14% & 24%; 31% & 21% reported moderate-severe symptom burden & fatigue which were similar in MGUS & SMM: #mmsm

#Myeloma Paper of the Day: Study of efficacy of isatuximab/pom/dex in pts w/ myeloma refractory to daratumumab finds median PFS of 5.8 months (12-month PFS 30.6%); Hb <11.8 g/L predicted 3.5x increased risk of progression, high risk FISH was 10x: #mmsm

RT @oncodaily: Myeloma Paper of the Day, February 3rd, suggested by @Myeloma_Doc @klcelotto @MohdAmmadUdDin #Can…

#Myeloma Paper of the Day: Pilot study of spot urine protein/creatinine ratio as an alternative to 24-hour urine collection for measuring proteinuria in patients (N=40) with myeloma finds good correlation between the two: #mmsm

#Myeloma Paper of the Day: Nationwide, population-based study in Netherlands on factors & considerations in no-treatment decisions in pts w/ heme malignancies finds primary reason related to physical condition, 2nd reason was patient/family choice: #mmsm

RT @oncodaily: Myeloma Paper of the Day, January 31st, suggested by @Myeloma_Doc #Cancer #OncoDaily #MedEd #MedX…

#Myeloma Paper of the Day: Targeting the ABCD1-ACOX1-MET/IGF1R axis suppresses myeloma, in part by promoting the accumulation of very long chain fatty acid-containing cerebrosides, revealing a specific metabolic vulnerability: #mmsm

RT @oncodaily: @Myeloma_Doc We would like to inform you that your post has been published on Thank you for sharing…

#Myeloma Paper of the Day: Comparative study of AL & ATTR #amyloidosis w/ cardiomyopathy finds diagnostic utility of relative apical sparing index (RASI) more remarkable in TTR-CM vs. AL-CM, & difference in relationship of RASI w/ LV wall thickness: #mmsm

RT @oncodaily: @Myeloma_Doc We would like to inform you that your post has been published on Thank you for sharing…

RT @oncodaily: Myeloma Paper of the Day, January 29th, suggested by @Myeloma_Doc #Cancer #OncoDaily #MedEd #MedX…

#Myeloma Paper of the Day: Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) may safely induce disease remissions in relapsed, refractory myeloma w/o CRS or ICANS though median PFS was only 6.0 months: #mmsm

#Myeloma Paper of the Day: Study of time-dependent recovery of renal impairment in patients with newly diagnosed myeloma finds 42.9% improved renal function @ 3 months after initiation of treatment but further improvement not observed at 6 months: #mmsm